Do analysts recommend CAPS or LEXX?

Lexaria Bioscience has a consensus target price of $1.50, suggesting a potential upside of 145.90%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Lexaria Bioscience is more favorable than Capstone Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Capstone Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate MAAQ or CAPS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mana Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Capstone Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, MAAQ or CAPS?

Mana Capital Acquisition has higher earnings, but lower revenue than Capstone Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mana Capital Acquisition N/A N/A N/A N/A N/A Capstone Therapeutics $48.11M 0.08 -$21.23M -$3.37 N/A

Do analysts recommend APLT or CAPS?

Applied Therapeutics presently has a consensus price target of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Applied Therapeutics is more favorable than Capstone Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Applied Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Capstone Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer CAPS or NAII?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Capstone Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Natural Alternatives International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate CAPS or QCLS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Capstone Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Capstone Therapeutics (CAPS) Competitors

$0.30 +0.01 (+1.69%)

As of 10:15 AM Eastern

Compare

CAPS vs. LEXX, MAAQ, APLT, NAII, and QCLS

Should you buy Capstone Therapeutics stock or one of its competitors? MarketBeat compares Capstone Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Capstone Therapeutics include Lexaria Bioscience (LEXX), Mana Capital Acquisition (MAAQ), Applied Therapeutics (APLT), Natural Alternatives International (NAII), and Mymd Pharmaceuticals (QCLS). These companies are all part of the "pharmaceutical products" industry.

How does Capstone Therapeutics compare to Lexaria Bioscience?

Capstone Therapeutics (NASDAQ:CAPS) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

2.6% of Capstone Therapeutics shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 39.3% of Capstone Therapeutics shares are owned by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Capstone Therapeutics had 2 more articles in the media than Lexaria Bioscience. MarketBeat recorded 3 mentions for Capstone Therapeutics and 1 mentions for Lexaria Bioscience. Lexaria Bioscience's average media sentiment score of 0.62 beat Capstone Therapeutics' score of 0.62 indicating that Lexaria Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Capstone Therapeutics	Positive
Lexaria Bioscience	Positive

Lexaria Bioscience has a consensus target price of $1.50, suggesting a potential upside of 145.90%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Lexaria Bioscience is more favorable than Capstone Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Capstone Therapeutics has a beta of -1.54, meaning that its share price is 254% less volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

Lexaria Bioscience has lower revenue, but higher earnings than Capstone Therapeutics. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Capstone Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capstone Therapeutics	$48.11M	0.08	-$21.23M	-$3.37	N/A
Lexaria Bioscience	$710K	21.30	-$11.90M	-$0.47	N/A

Lexaria Bioscience has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -41.26%. Capstone Therapeutics' return on equity of -114.15% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capstone Therapeutics	-41.26%	-114.15%	-39.74%
Lexaria Bioscience	N/A	-206.02%	-162.53%

Summary

Lexaria Bioscience beats Capstone Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Capstone Therapeutics compare to Mana Capital Acquisition?

Mana Capital Acquisition (NASDAQ:MAAQ) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

Mana Capital Acquisition has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -41.26%. Mana Capital Acquisition's return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mana Capital Acquisition	N/A	N/A	N/A
Capstone Therapeutics	-41.26%	-114.15%	-39.74%

68.4% of Mana Capital Acquisition shares are owned by institutional investors. Comparatively, 2.6% of Capstone Therapeutics shares are owned by institutional investors. 39.3% of Capstone Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Capstone Therapeutics had 3 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 3 mentions for Capstone Therapeutics and 0 mentions for Mana Capital Acquisition. Capstone Therapeutics' average media sentiment score of 0.62 beat Mana Capital Acquisition's score of 0.00 indicating that Capstone Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Mana Capital Acquisition	Neutral
Capstone Therapeutics	Positive

Mana Capital Acquisition has higher earnings, but lower revenue than Capstone Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A
Capstone Therapeutics	$48.11M	0.08	-$21.23M	-$3.37	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mana Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Capstone Therapeutics beats Mana Capital Acquisition on 5 of the 9 factors compared between the two stocks.

How does Capstone Therapeutics compare to Applied Therapeutics?

Applied Therapeutics (NASDAQ:APLT) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

98.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 2.6% of Capstone Therapeutics shares are held by institutional investors. 1.6% of Applied Therapeutics shares are held by insiders. Comparatively, 39.3% of Capstone Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Applied Therapeutics has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -41.26%. Capstone Therapeutics' return on equity of -114.15% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
Capstone Therapeutics	-41.26%	-114.15%	-39.74%

Applied Therapeutics presently has a consensus price target of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Applied Therapeutics is more favorable than Capstone Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Capstone Therapeutics had 3 more articles in the media than Applied Therapeutics. MarketBeat recorded 3 mentions for Capstone Therapeutics and 0 mentions for Applied Therapeutics. Capstone Therapeutics' average media sentiment score of 0.62 beat Applied Therapeutics' score of 0.00 indicating that Capstone Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Applied Therapeutics	Neutral
Capstone Therapeutics	Positive

Applied Therapeutics has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market. Comparatively, Capstone Therapeutics has a beta of -1.54, meaning that its stock price is 254% less volatile than the broader market.

Capstone Therapeutics has higher revenue and earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than Capstone Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
Capstone Therapeutics	$48.11M	0.08	-$21.23M	-$3.37	N/A

Summary

Capstone Therapeutics beats Applied Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Capstone Therapeutics compare to Natural Alternatives International?

Capstone Therapeutics (NASDAQ:CAPS) and Natural Alternatives International (NASDAQ:NAII) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

Natural Alternatives International has a net margin of -10.13% compared to Capstone Therapeutics' net margin of -41.26%. Natural Alternatives International's return on equity of -12.21% beat Capstone Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capstone Therapeutics	-41.26%	-114.15%	-39.74%
Natural Alternatives International	-10.13%	-12.21%	-5.30%

2.6% of Capstone Therapeutics shares are owned by institutional investors. Comparatively, 32.4% of Natural Alternatives International shares are owned by institutional investors. 39.3% of Capstone Therapeutics shares are owned by insiders. Comparatively, 20.8% of Natural Alternatives International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Capstone Therapeutics has a beta of -1.54, indicating that its stock price is 254% less volatile than the broader market. Comparatively, Natural Alternatives International has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

In the previous week, Capstone Therapeutics had 1 more articles in the media than Natural Alternatives International. MarketBeat recorded 3 mentions for Capstone Therapeutics and 2 mentions for Natural Alternatives International. Capstone Therapeutics' average media sentiment score of 0.62 beat Natural Alternatives International's score of 0.45 indicating that Capstone Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Capstone Therapeutics	Positive
Natural Alternatives International	Neutral

Natural Alternatives International has higher revenue and earnings than Capstone Therapeutics. Natural Alternatives International is trading at a lower price-to-earnings ratio than Capstone Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capstone Therapeutics	$48.11M	0.08	-$21.23M	-$3.37	N/A
Natural Alternatives International	$129.86M	0.12	-$13.57M	-$2.39	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Natural Alternatives International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Natural Alternatives International beats Capstone Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Capstone Therapeutics compare to Mymd Pharmaceuticals?

Capstone Therapeutics (NASDAQ:CAPS) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

2.6% of Capstone Therapeutics shares are owned by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. 39.3% of Capstone Therapeutics shares are owned by company insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mymd Pharmaceuticals has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -41.26%. Mymd Pharmaceuticals' return on equity of -76.40% beat Capstone Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capstone Therapeutics	-41.26%	-114.15%	-39.74%
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%

Capstone Therapeutics has a beta of -1.54, meaning that its share price is 254% less volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.17, meaning that its share price is 117% more volatile than the broader market.

In the previous week, Capstone Therapeutics had 2 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 3 mentions for Capstone Therapeutics and 1 mentions for Mymd Pharmaceuticals. Mymd Pharmaceuticals' average media sentiment score of 1.87 beat Capstone Therapeutics' score of 0.62 indicating that Mymd Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Capstone Therapeutics	Positive
Mymd Pharmaceuticals	Very Positive

Mymd Pharmaceuticals has lower revenue, but higher earnings than Capstone Therapeutics. Mymd Pharmaceuticals is trading at a lower price-to-earnings ratio than Capstone Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capstone Therapeutics	$48.11M	0.08	-$21.23M	-$3.37	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A

Summary

Mymd Pharmaceuticals beats Capstone Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Capstone Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CAPS vs. The Competition

Export

Metric	Capstone Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.79M	$3.39B	$6.49B	$12.31B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-0.09	20.05	24.05	24.76
Price / Sales	0.08	325.48	542.61	168.32
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	0.22	8.16	10.69	6.90
Net Income	-$21.23M	$23.89M	$3.57B	$337.45M
7 Day Performance	-5.66%	3.66%	1.56%	2.84%
1 Month Performance	6.76%	1.69%	2.49%	4.78%
1 Year Performance	-83.24%	46.95%	26.51%	33.08%

Capstone Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CAPS Capstone Therapeutics	0.5615 of 5 stars	$0.30 +1.7%	N/A	-83.5%	$3.79M	$48.11M	N/A	38	Short Interest Increase Gap Down
LEXX Lexaria Bioscience	2.2579 of 5 stars	$0.65 +1.5%	$1.50 +132.0%	-37.1%	$16.03M	$368K	N/A	7	Gap Up
MAAQ Mana Capital Acquisition	N/A	$1.96 -7.1%	N/A	-51.7%	$15.93M	N/A	N/A	1
APLT Applied Therapeutics	1.425 of 5 stars	$0.10 flat	$1.00 +870.9%	N/A	$15.86M	$1M	N/A	30
NAII Natural Alternatives International	0.6034 of 5 stars	$2.52 +0.6%	N/A	-28.9%	$15.80M	$129.86M	N/A	290	Short Interest Increase Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CAPS) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Capstone Therapeutics (CAPS) Competitors

CAPS vs. LEXX, MAAQ, APLT, NAII, and QCLS

How does Capstone Therapeutics compare to Lexaria Bioscience?

Summary

How does Capstone Therapeutics compare to Mana Capital Acquisition?

Summary

How does Capstone Therapeutics compare to Applied Therapeutics?

Summary

How does Capstone Therapeutics compare to Natural Alternatives International?

Summary

How does Capstone Therapeutics compare to Mymd Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPS vs. The Competition

Capstone Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Capstone Therapeutics (CAPS) Competitors

CAPS vs. LEXX, MAAQ, APLT, NAII, and QCLS

How does Capstone Therapeutics compare to Lexaria Bioscience?

Do insiders and institutionals hold more shares of CAPS or LEXX?

Does the media prefer CAPS or LEXX?

Do analysts recommend CAPS or LEXX?

Which has more risk and volatility, CAPS or LEXX?

Which has stronger valuation and earnings, CAPS or LEXX?

Is CAPS or LEXX more profitable?

Summary

How does Capstone Therapeutics compare to Mana Capital Acquisition?

Is MAAQ or CAPS more profitable?

Do insiders and institutionals have more ownership in MAAQ or CAPS?

Does the media prefer MAAQ or CAPS?

Which has stronger earnings and valuation, MAAQ or CAPS?

Do analysts rate MAAQ or CAPS?

Summary

How does Capstone Therapeutics compare to Applied Therapeutics?

Do institutionals and insiders believe in APLT or CAPS?

Is APLT or CAPS more profitable?

Do analysts recommend APLT or CAPS?

Does the media favor APLT or CAPS?

Which has more risk & volatility, APLT or CAPS?

Which has better earnings and valuation, APLT or CAPS?

Summary

How does Capstone Therapeutics compare to Natural Alternatives International?

Is CAPS or NAII more profitable?

Do institutionals and insiders have more ownership in CAPS or NAII?

Which has more volatility and risk, CAPS or NAII?

Does the media refer more to CAPS or NAII?

Which has preferable earnings & valuation, CAPS or NAII?

Do analysts prefer CAPS or NAII?

Summary

How does Capstone Therapeutics compare to Mymd Pharmaceuticals?

Do institutionals and insiders hold more shares of CAPS or QCLS?

Do analysts rate CAPS or QCLS?

Is CAPS or QCLS more profitable?

Which has more volatility and risk, CAPS or QCLS?

Does the media favor CAPS or QCLS?

Which has stronger earnings & valuation, CAPS or QCLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPS vs. The Competition

Capstone Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools